Analytical Data
-
Gene name
PSMD13
- Application
-
Alternative Names
p40.5; Rpn9; 26S proteasome non-ATPase regulatory subunit 13; 26S proteasome regulatory subunit RPN9
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UNM6
-
Expression Region
Met1~Thr378
-
Molecular Weight
47kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMD13, a crucial component of the 26S proteasome, plays a vital role in the ubiquitin-proteasome system, which is responsible for the degradation of misfolded and regulatory proteins in eukaryotic cells. This protein is implicated in several cellular processes, including protein quality control, cell cycle regulation, and modulation of various signaling pathways. Research into PSMD13 has gained momentum due to its association with several diseases, particularly cancer and neurodegenerative disorders. Understanding its structure and function is essential for developing therapeutic strategies aimed at manipulating proteasome activity. Recombinant PSMD13 protein is often produced for biochemical assays and structural studies, allowing researchers to explore its interactions with ubiquitin-conjugating enzymes and other proteasomal subunits. By elucidating the role of PSMD13 in protein degradation, scientists hope to uncover novel insights into the pathogenesis of diseases associated with proteasome dysfunction, potentially leading to the identification of new drug targets and therapeutic interventions.
